MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space
Executive Summary
The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.
You may also be interested in...
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
ICER: Antibodies For MS – Including TG’s – Need Big Price Cut For Cost-Effectiveness
The pricing watchdog said it found “insufficient evidence” to differentiate the benefit of TG’s ublituximab from other antibodies already on the market for multiple sclerosis.
HEC Pharm Wins Key Reversal In US Gilenya Dosing Patent Fight
China’s HEC Pharm, the last ANDA filer for fingolimod standing in patent litigation, has won a key invalidity challenge against a dosing-regimen patent shielding the multiple sclerosis treatment. However, the Federal Circuit was split on whether it had applied a heightened standard for negative claim limitations.